AAP
AARD

Arax Advisory Partners’s Aardvark Therapeutics AARD Stock Holding History

Arax Advisory Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23 Buy
+24
New +$249 ﹤0.01% 3711
2025
Q4 		– Sell
-21
Closed -$280 – 4624
2025
Q3 		$280 Buy
+21
New +$237 ﹤0.01% 3422

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arax Advisory Partners's AARD Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 24 shares worth $23. The stake represents ﹤0.01% of the portfolio and ranks #3711 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in AARD as recently as Q3 2025.

Arax Advisory Partners first reported a position in AARD in Q3 2025 and has held it in 2 quarters since. The position peaked at $280 in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Arax Advisory Partners held 24 shares of Aardvark Therapeutics worth $23 as of Q1 2026.
  • Aardvark Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3711 holding.
  • Arax Advisory Partners first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Aardvark Therapeutics position peaked at $280 in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.